What is a bulk drugs project report?
A bulk drugs project report is a detailed project report (DPR) for a plant that makes active pharmaceutical ingredients (APIs) by chemical synthesis. It sets out the molecules, reaction steps, reactors, solvents, drug licence and environmental clearance, project cost, five-year projections, DSCR and break-even that a bank or investor reviews before funding.
Promoters use it to size a multipurpose API unit and raise a term loan; lenders and investors use it to judge whether the plant can repay.
Also known as: API manufacturing project report, bulk drug plant DPR, active pharmaceutical ingredient project report, bulk drug manufacturing business plan.
Bulk drugs manufacturing plant cost in India
Our sample report models a multipurpose API unit of 1,000 kg per day, running 330 days a year and selling at ₹914 per kg. It starts at 60% of capacity and reaches 80% in Year 5, because formulators take time to approve each new supplier.
Plant and machinery is the biggest block at ₹724.42 lakh, followed by building and civil works at ₹357.79 lakh. Reactors, solvent recovery and effluent treatment carry most of the machinery cost, which is why an API plant costs far more per kilogram than a formulation unit of similar output.
| Land and site development | 90.55 |
|---|---|
| Building and civil works | 357.79 |
| Plant and machinery | 724.42 |
| Other fixed assets | 80.56 |
| Contingencies | 54.11 |
| Preliminary and pre-operative | 32.69 |
| Working capital margin | 68.23 |
| Total | 1,408.35 |
| Promoter's contribution (25%) | 352.09 |
|---|---|
| Term loan from bank (75%) | 1,056.26 |
| Cash credit limit (separate) | 204.68 |
| Total project cost | 1,408.35 |
Term loan at 10.5% with a 6-month moratorium and 54 monthly instalments; lowest yearly DSCR 1.65. All figures are illustrative.
Bulk drugs manufacturing process, step by step
Most generic APIs are made in batches through several chemical stages. Each stage repeats the same cycle in the same reactors, and the last stage ends in a pure, dried powder that is tested against the pharmacopoeia monograph.
- Reaction
Starting materials, reagents and solvent are charged to a glass lined or stainless steel reactor. The batch is held at a set temperature, often under nitrogen, until in-process tests show completion.
- Work-up
The mass is quenched, the layers are separated and the product layer is washed to remove salts and side products.
- Crystallisation
The crude product is dissolved, treated with activated carbon, filtered and cooled with chilled brine so crystals form at the right size and purity.
- Centrifuging
A centrifuge or nutsche filter separates the crystals from the mother liquor, and the wet cake is washed with fresh solvent.
- Drying
The wet cake is dried in a vacuum tray or fluid bed dryer until loss on drying and residual solvents meet the specification.
- Milling and blending
The powder is milled to the particle size the buyer needs, sifted and blended into one homogeneous batch in a clean area.
- Solvent recovery
Mother liquors and spent solvents are distilled, tested and reused; the residue goes for incineration.
- Testing and release
Quality control tests each batch by HPLC and GC, and quality assurance releases it with a certificate of analysis.
Multipurpose or dedicated: which bulk drug plant model fits you?
The biggest early choice is what the reactors will make. It sets the machinery list, the approvals you file and how fast sales build up.
| Multipurpose API plant | Common reactors run several off-patent molecules in campaigns. Flexible, and the usual start for a new promoter, but every product change needs cleaning and cleaning validation. |
|---|---|
| Intermediates first | Make advanced intermediates for larger API makers before moving to APIs. Lighter GMP load and faster sales, at lower margins per kilogram. |
| Dedicated single-molecule plant | One high-volume API in a line built for it. Lowest cost per kilogram, but the whole project rides on one product's price. |
| Contract manufacturing | Make a molecule to a client's process and specification. Sales are steadier, but you need a client in hand before the bank will count it. |
Clearance filings for small Karnataka units list from 9 to more than 20 products made in rotation; one runs any two at a time, another any twelve.
Raw materials for bulk drugs
Key starting materials (KSMs) and intermediates are 62% of raw material cost in our sample, and raw materials as a whole are 46.3% of sales. Many KSMs are still imported, so a report should name at least two suppliers for each one and show what a price rise does to DSCR.
| Raw material | Share of cost | Year 3 (₹ lakh) |
|---|---|---|
| Key starting materials and intermediates | 62% | 606.33 |
| Make-up solvents | 20% | 195.59 |
| Reagents and catalysts | 12% | 117.35 |
| Activated carbon and filter aids | 6% | 58.68 |
| Total | 100% | 977.95 |
Make-up solvent is only the solvent lost in each cycle. The rest comes back from the recovery column.
Machinery for a bulk drug plant
Reactors are the largest item. Glass lined vessels handle acids and corrosive reagents; stainless steel vessels take solvents, distillation and general work.
| Equipment | What it does | Sample cost (₹ lakh) |
|---|---|---|
| SS and glass lined reactors | Run the reactions, work-up and crystallisation | 202.84 |
| Solvent recovery and distillation system | Recovers solvent from mother liquors for reuse | 101.42 |
| Centrifuges and nutsche filters | Separate crystals from liquor | 86.93 |
| Boiler, chilling plant and cooling tower | Steam for heating, brine for cooling | 86.93 |
| Vacuum tray and fluid bed dryers | Dry the wet cake to specification | 72.44 |
| Effluent treatment plant with MEE | Treats process effluent and evaporates high-salt streams | 65.20 |
| QC laboratory with HPLC and GC | Tests assay, impurities and residual solvents | 65.20 |
| Milling, sifting and blending equipment | Sets particle size and blends batches | 43.46 |
| Total plant and machinery | 724.42 | |
Costs are the sample report's estimates. Reactor sizes and the number of trains depend on your molecules and batch sizes, so get current quotations before you finalise.
Utilities, effluent and manpower for an API unit
Steam, chilled brine and effluent handling decide whether an API plant runs to plan. They also carry much of the regulator's attention.
| Power and fuel | ₹124.51 lakh in Year 3 of the sample, about 5.9% of sales. A small Bidar unit of 9 MT per month drew 180 kVA from the grid. |
|---|---|
| Steam and cooling | A boiler supplies steam for reactor heating and distillation; a chilling plant supplies brine for crystallisation and solvent condensers. |
| Water | One Yadgir filing for about 99 MT per month planned 78.4 kilolitres per day, mostly for process, boiler feed and cooling tower. |
| Effluent | High-salt process streams go to a multiple effect evaporator (MEE); other streams are treated on site or sent to a common effluent plant where one exists. |
| Manpower | 46 people in the sample: 7 in management and administration, 16 skilled operators and 23 semi-skilled and unskilled workers. |
| Technical staff | The drug licence needs named competent persons for production, quality assurance and quality control, with qualification and experience proofs. |
Licences and clearances for a bulk drug unit
Approvals take longer for an API plant than for most factories, so they belong in the project schedule from the first month. Order matters: environmental clearance and pollution consent come before the drug licence inspection.
| Environmental clearance | Required under item 5(f), synthetic organic chemicals, of the EIA Notification 2006. Units in a notified industrial area are usually Category B at state level; others can be Category A. |
|---|---|
| Pollution board consent | Consent to establish and to operate from the State Pollution Control Board. State lists such as Odisha's place pharmaceuticals in the Red category, the strictest. |
| Drug manufacturing licence | Application on Form 24 to the State Drugs Licensing Authority under the Drugs Rules, 1945, with site plan, equipment lists, product list and technical staff details. |
| Good manufacturing practices | Revised Schedule M, notified by G.S.R. 922(E) on 28 December 2023. The compliance windows for existing units have closed, so a new plant must be built to it. |
| New drug permission | Needed from the Central Licensing Authority before a state licence if the molecule counts as a new drug in India. |
| Business registrations | Udyam and GST registration, factory licence and fire NOC under state rules. |
Checked October 2026. Requirements differ by state; confirm with the state drugs controller and pollution board.
Who buys bulk drugs, and how a new unit wins orders
Bulk drugs are sold by weight to formulation makers, who need every batch to match the specification they have filed with the regulator. A new unit usually starts with a few off-patent molecules and wins buyers on consistent purity, impurity profile, documents and on-time supply.
Government policy supports domestic API supply. The PLI scheme for bulk drugs covers 41 products, and bulk drug parks with common infrastructure were approved in Andhra Pradesh, Gujarat and Himachal Pradesh.
- Tablet, capsule and injectable formulation makers
- Contract and loan-licence manufacturers
- Pharmaceutical exporters
- Bulk drug traders and distributors
- Larger API makers buying intermediates
Plan for the approval lag: a formulator tests validation batches and samples before placing a regular order. That is why the sample starts at 60% of capacity and why lenders look closely at first-year working capital.
Mistakes that weaken a bulk drugs project report
- Assuming full solvent recovery
Some solvent is lost every cycle. Batch data in one Bidar filing shows about 95% recovery for toluene and THF, and the make-up solvent must be costed.
- One average yield for every molecule
Each product has its own stages, yields and batch time. Production should be built product by product, with changeover and cleaning days deducted.
- Treating effluent as an afterthought
An MEE and solvent incineration route are part of the clearance. Leaving them out understates cost and stalls consent.
- No time for clearance and buyer approval
Months for environmental clearance and buyer qualification push sales back. Interest during that time and the moratorium must match.
- Counting PLI income without eligibility
The incentive applies only to notified products at set minimum capacities. Projections that include it without a selection letter will not hold up.
How NPCS helps you set up a bulk drug plant
- Molecule and capacity choiceShortlist off-patent APIs or intermediates and size the reactor trains for them.
- Process and equipment listStage-wise material balance, reactor sizing, solvent recovery and utilities.
- Bank-ready project reportProjections, DSCR and working capital built for the approval lag your lender will ask about.
- Approvals roadmapEnvironmental clearance, pollution consent, drug licence and Schedule M steps in order for your state.
NPCS has prepared project reports for pharmaceutical units since 1994, and its published client list records 67 assignments in the pharmaceuticals sector, including API and paracetamol plants.
What's inside the bulk drugs sample report
- Introduction
- Uses and applications
- Market potential
- Manufacturing process
- Raw materials
- Plant and machinery
- Land, building and utilities
- Manpower
- Licences and approvals
- Project cost and means of finance
- Working capital
- Projected profitability
- Cash flow statement
- Projected balance sheet
- Depreciation
- Term loan repayment
- Debt service coverage
- Break-even analysis
- Financial ratios
- Key assumptions
- Conclusion
- Monthly loan repayment schedule
19 pages, five-year projections, illustrative figures.
Open sample reportFree sample or a report for your project?
| What you get | Free sample | NPCS report for your project |
|---|---|---|
| Capacity and location | Typical unit | Your capacity, site and state |
| Figures | Illustrative | Built on current prices and quotations |
| Machinery suppliers and quotations | No | Yes |
| Market survey for your region | No | Yes |
| Bank or scheme format (PMEGP, term loan) | No | Yes |
| Use for a loan application | No | Yes |
What clients say about NPCS
4.7
264 Google reviews, as of 20 Oct 2026
Clients most often mention
- feasibility reports 18
- project report 16
- helpful for startups 15
- detailed reports 8
-
Excellent experience with Niir Project Consultancy Services. Their Techno-Economic Feasibility Reports are incredibly detailed and backed by solid market data.
Piyush Singh, Google review, 2026
-
Niir Project Consultancy Services offers excellent guidance for business setup. Their market survey and feasibility reports saved us a lot of time and helped us make informed decisions. Highly recommended
Saroj Yadav, Google review, 2026 View on Google
-
In an era of information overload, NIIR stands out for its precision. Their technical consultancy and market feasibility studies are world-class.
Shrishti Gautam, Google review, 2026
-
NIIR Project Consultancy Services provides useful books and reports for students, entrepreneurs, and small businesses. Their content is easy to understand and focuses on practical ideas for starting and managing industries. Overall, NIIR is helpful for learning about business and project planning.
Raj Yadav, Google review, 2026
Bulk Drugs project report: frequently asked questions
How much does it cost to set up a bulk drug manufacturing plant in India?
A small multipurpose API or intermediates unit in an industrial estate usually needs about ₹5–10 crore. A 1–3 MT per day plant needs about ₹12–30 crore, including effluent treatment and working capital margin. Our sample report models a 1,000 kg per day unit at ₹1,408 lakh. These ranges are indicative; your report costs the plant for your molecules and site.
What is the difference between bulk drugs and formulations?
Bulk drugs, or APIs, are the active chemical in a medicine, sold as powder by the kilogram. Formulations are the finished tablets, capsules, syrups or injections made by mixing the API with excipients. A bulk drug plant is a chemical plant with reactors and solvent handling; a formulation plant is a clean-room dosage plant. The two need separate project reports.
Which licence is needed to manufacture bulk drugs?
You apply on Form 24 to the State Drugs Licensing Authority for a licence to manufacture drugs under the Drugs Rules, 1945, naming each product. The plant must meet revised Schedule M good manufacturing practices and have competent technical staff for production, quality assurance and quality control. A new drug also needs permission from the Central Licensing Authority first.
Is environmental clearance required for an API manufacturing unit?
Yes. Bulk drug and intermediate plants fall under item 5(f), synthetic organic chemicals, of the EIA Notification 2006. A unit inside a notified industrial area is usually appraised at state level as Category B; other sites can be Category A. Plan several months for the clearance, then pollution board consent, before construction finishes.
Is bulk drug manufacturing profitable?
In our illustrative sample, a 1,000 kg per day unit selling at ₹914 per kg earns a 23% return on investment in Year 3. Break-even is at 34% of capacity and payback takes about 3.4 years. Real margins depend on the molecules chosen, solvent recovery, batch yields and how quickly formulators approve your material.
Can a small bulk drug unit get the PLI incentive?
Only if it makes one of the 41 notified key starting materials, drug intermediates or APIs and meets that product's minimum capacity in a scheme round. The scheme has an outlay of ₹6,940 crore and runs to 2029-30. Most new multipurpose units do not qualify, so the project report should not count on PLI income.
Is the sample report free and can I use it for a loan?
The sample is free to view and download. It is an illustrative report that shows the format and depth of an NPCS report. Its figures are representative and not based on a real project, so do not submit it to a bank. For a loan, NPCS prepares a report for your own molecules, capacity, site and lender.
Sources and references
- Lok Sabha Unstarred Question No. 50: PLI schemes and Bulk Drug ParksMinistry of Chemicals and Fertilizers, Lok Sabha, checked Oct 2026
- Addendum to the PLI scheme guidelines for bulk drugs (4 May 2026)Department of Pharmaceuticals, Government of India, checked Oct 2026
- Parliament answer on revised Schedule M (G.S.R. 922(E))Ministry of Chemicals and Fertilizers, Parliament of India, checked Oct 2026
- Drugs manufacturing licence: application on Form 24 and documentsDirectorate of Health Safety and Regulation, Government of Himachal Pradesh, checked Oct 2026
- Standard terms of reference for a bulk drug unit under item 5(f)PARIVESH, Ministry of Environment, Forest and Climate Change, checked Oct 2026
- Pre-feasibility report for a bulk drug unit, Kolhar Industrial Area, BidarMinistry of Environment, Forest and Climate Change (environment clearance portal), checked Oct 2026
- Pre-feasibility report for a bulk drug and intermediates unit, Kadechur, YadgirMinistry of Environment, Forest and Climate Change (environment clearance portal), checked Oct 2026
- List of Red category industriesState Pollution Control Board, Odisha, checked Oct 2026
The NPCS project team, led by Ajay Kumar Gupta
This page and its sample report are prepared and reviewed by the NPCS project team, which has written techno-economic feasibility studies and detailed project reports since 1994.
Ajay Kumar Gupta founded Niir Project Consultancy Services (NPCS) and leads the organisation. With 40 years of experience in MSME project consulting, he has built the team that has delivered more than 28,000 project reports for clients worldwide, helping entrepreneurs plan and finance profitable manufacturing businesses.
- Published
- Last updated
- Next review
- Oct 2027
- Reviewed by
- NPCS project team
This page is reviewed every 12 months, or sooner when scheme limits, GST rates, BIS rules or pollution categories change. The sample report is illustrative: its figures are generated from industry-typical ratios for a unit of this size, checked so every statement balances, and are not taken from any client project.